Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer (2015)
- Authors:
- Mackey, John R.
- Ramos-Vazquez, Manuel
- Oleg Lipatov,
- McCarthy, Nicole
- Krasnozhon, Dmitriy
- Semiglazov, Vladimir
- Manikhas, Alexey
- Gelmon, Karen A.
- Konecny, Gottfried E.
- Webster, Marc
- Hegg, Roberto
- Verma, Sunil
- Gorbunova, Vera
- Gerges, Dany Abi
- Thireau, Francois
- Fung, Helena
- Simms, Lorinda
- Buyse, Marc
- Ibrahim, Ayman
- Martin, Miguel
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1200/JCO.2014.57.1513
- Subjects: NEOPLASIAS MAMÁRIAS; TRATAMENTO (RESULTADOS); METÁSTASE NEOPLÁSICA; ANTINEOPLÁSICOS (CLASSIFICAÇÃO)
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Journal of Clinical Oncology
- ISSN: 0732-183X
- Volume/Número/Paginação/Ano: v. 33, n. 2, p. 141-148, 2015
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
MACKEY, John R. et al. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. Journal of Clinical Oncology, v. 33, n. 2, p. 141-148, 2015Tradução . . Disponível em: https://doi.org/10.1200/JCO.2014.57.1513. Acesso em: 24 abr. 2024. -
APA
Mackey, J. R., Ramos-Vazquez, M., Oleg Lipatov,, McCarthy, N., Krasnozhon, D., Semiglazov, V., et al. (2015). Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. Journal of Clinical Oncology, 33( 2), 141-148. doi:10.1200/JCO.2014.57.1513 -
NLM
Mackey JR, Ramos-Vazquez M, Oleg Lipatov, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Gerges DA, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martin M. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer [Internet]. Journal of Clinical Oncology. 2015 ; 33( 2): 141-148.[citado 2024 abr. 24 ] Available from: https://doi.org/10.1200/JCO.2014.57.1513 -
Vancouver
Mackey JR, Ramos-Vazquez M, Oleg Lipatov, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Gerges DA, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martin M. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer [Internet]. Journal of Clinical Oncology. 2015 ; 33( 2): 141-148.[citado 2024 abr. 24 ] Available from: https://doi.org/10.1200/JCO.2014.57.1513 - Galactorreia: sindrome hiperprolactinemica
- Como diagnosticar e tratar sindrome do climaterio
- Hormonioterapia de reposicao e cancer de mama
- Prevencao da osteoporose
- Câncer de mama
- Recursos terapêuticos na doente terminal
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4
- Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
- Distrofias vulvares
Informações sobre o DOI: 10.1200/JCO.2014.57.1513 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
